<DOC>
	<DOCNO>NCT01446250</DOCNO>
	<brief_summary>This study ass safety efficacy alisporivir ( ALV ) boceprevir ( BOC ) , combination Peginterferon alfa-2a ( PEG ) Ribavirin ( RBV ) , African American participant never receive treatment chronic hepatitis C ( HCV ) genotype 1 infection .</brief_summary>
	<brief_title>Alisporivir ( Deb025 ) Boceprevir Triple Therapies African American Participants Not Previously Treated Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : Chronic HCV genotype 1 infection No previous treatment HCV infection African American ethnicity Serum HCV RNA ≥ 1000 IU/ml , assess quantitative polymerase chain reaction equivalent screen visit , upper limit A liver biopsy within 3 year prior baseline Exclusion criterion : HCV genotype different genotype 1 coinfection HCV genotype Coinfection Hepatitis B HIV Any cause relevant liver disease HCV Presence history hepatic decompensation Alanine aminotransferase ( ALT ) ≥ 10 time ULN , 1 episode elevate bilirubin ( &gt; ULN ) past 6 month Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
</DOC>